Safety

Precose (acarbose) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

March 2015

Summary View

PRECAUTIONS

Laboratory Tests
  • Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking acarbose. Use alternative methods to monitor for glycemic control.
     

 

February 2012 

Summary View 

ADVERSE REACTIONS

Postmarketing Adverse Event Reports
  • Pneumatosis Cystoides Intestinalis: There have been rare postmarketing reports of pneumatosis cystoides intestinalis associated with the use of alpha-glucosidase inhibitors, including Precose. Pneumatosis cystoides intestinalis may present with symptoms of diarrhea, mucus discharge, rectal bleeding, and constipation. Complications may include pneumoperitoneum, volvulus, intestinal obstruction, intussusception, intestinal hemorrhage, and intestinal perforation. If pneumatosis cystoides intestinalis is suspected, discontinue Precose and perform the appropriate diagnostic imaging.

 

March 2011

Summary View

ADVERSE REACTIONS

  • thrombocytopenia, pneumatosis cystoidis intestinalis, and fulminant hepatitis with fatal outcome

 

Page Last Updated: 04/15/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.